S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
NASDAQ:PTGX

Protagonist Therapeutics Stock Forecast, Price & News

$29.33
-2.48 (-7.80%)
(As of 01/21/2022 04:00 PM ET)
Add
Compare
Today's Range
$29.04
$32.16
50-Day Range
$28.94
$36.71
52-Week Range
$12.80
$50.54
Volume
1.09 million shs
Average Volume
697,918 shs
Market Capitalization
$1.40 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.16
30 days | 90 days | 365 days | Advanced Chart
Receive PTGX News and Ratings via Email

Sign-up to receive the latest news and ratings for Protagonist Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Protagonist Therapeutics logo

About Protagonist Therapeutics

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline include PTG-300, PTG-200, and PN-943 The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Headlines

Protagonist Therapeutics (NASDAQ:PTGX) Shares Down 4.8%
January 20, 2022 |  americanbankingnews.com
Protagonist Therapeutics (NASDAQ:PTGX) Shares Gap Down to $34.75
January 14, 2022 |  americanbankingnews.com
/C O R R E C T I O N -- Protagonist Therapeutics, Inc./
January 4, 2022 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PTGX
Fax
N/A
Employees
79
Year Founded
N/A

Sales & Book Value

Annual Sales
$28.63 million
Book Value
$7.31 per share

Profitability

Net Income
$-66.15 million
Net Margins
-440.88%
Pretax Margin
-440.88%

Debt

Price-To-Earnings

Miscellaneous

Free Float
45,342,000
Market Cap
$1.40 billion
Optionable
Not Optionable

Company Calendar

Last Earnings
11/03/2021
Today
1/23/2022
Next Earnings (Estimated)
3/09/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.03 out of 5 stars

Medical Sector

611th out of 1,419 stocks

Pharmaceutical Preparations Industry

296th out of 685 stocks

Analyst Opinion: 3.5Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -












Protagonist Therapeutics (NASDAQ:PTGX) Frequently Asked Questions

Is Protagonist Therapeutics a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Protagonist Therapeutics in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Protagonist Therapeutics stock.
View analyst ratings for Protagonist Therapeutics
or view top-rated stocks.

How has Protagonist Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Protagonist Therapeutics' stock was trading at $7.16 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, PTGX stock has increased by 309.6% and is now trading at $29.33.
View which stocks have been most impacted by COVID-19
.

When is Protagonist Therapeutics' next earnings date?

Protagonist Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, March 9th 2022.
View our earnings forecast for Protagonist Therapeutics
.

How were Protagonist Therapeutics' earnings last quarter?

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) announced its quarterly earnings data on Wednesday, November, 3rd. The company reported ($0.70) EPS for the quarter, missing analysts' consensus estimates of ($0.67) by $0.03. The business had revenue of $10.29 million for the quarter, compared to analyst estimates of $3.43 million. Protagonist Therapeutics had a negative net margin of 440.88% and a negative trailing twelve-month return on equity of 35.08%.
View Protagonist Therapeutics' earnings history
.

What price target have analysts set for PTGX?

7 brokers have issued twelve-month price targets for Protagonist Therapeutics' shares. Their forecasts range from $40.00 to $93.00. On average, they expect Protagonist Therapeutics' share price to reach $59.71 in the next year. This suggests a possible upside of 103.6% from the stock's current price.
View analysts' price targets for Protagonist Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Protagonist Therapeutics' key executives?

Protagonist Therapeutics' management team includes the following people:
  • Dinesh V. Patel, President, Chief Executive Officer & Director
  • Donald A. Kalkofen, Chief Financial Officer
  • Mark L. Smythe, Vice President-Technology
  • David Y. Liu, Chief Scientific Officer (LinkedIn Profile)
  • Samuel R. Saks, Chief Medical Officer

What other stocks do shareholders of Protagonist Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Protagonist Therapeutics investors own include VBI Vaccines (VBIV), Viking Therapeutics (VKTX), ImmunoGen (IMGN), SCYNEXIS (SCYX), Energy Transfer (ET), Strongbridge Biopharma (SBBP), Verastem (VSTM), Dynavax Technologies (DVAX), Novavax (NVAX) and Sorrento Therapeutics (SRNE).

When did Protagonist Therapeutics IPO?

(PTGX) raised $70 million in an initial public offering (IPO) on Thursday, August 11th 2016. The company issued 5,800,000 shares at $11.00-$13.00 per share. Leerink Partners, Barclays and BMO Capital Markets served as the underwriters for the IPO.

What is Protagonist Therapeutics' stock symbol?

Protagonist Therapeutics trades on the NASDAQ under the ticker symbol "PTGX."

Who are Protagonist Therapeutics' major shareholders?

Protagonist Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Russell Investments Group Ltd. (0.34%), Kestra Advisory Services LLC (0.02%) and Cutler Group LP (0.00%). Company insiders that own Protagonist Therapeutics stock include David Y Liu, Dinesh V Ph D Patel, Harold E Selick and Sarah B Noonberg.
View institutional ownership trends for Protagonist Therapeutics
.

Which institutional investors are buying Protagonist Therapeutics stock?

PTGX stock was acquired by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Kestra Advisory Services LLC, and Cutler Group LP.
View insider buying and selling activity for Protagonist Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Protagonist Therapeutics?

Shares of PTGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Protagonist Therapeutics' stock price today?

One share of PTGX stock can currently be purchased for approximately $29.33.

How much money does Protagonist Therapeutics make?

Protagonist Therapeutics has a market capitalization of $1.40 billion and generates $28.63 million in revenue each year. The company earns $-66.15 million in net income (profit) each year or ($2.41) on an earnings per share basis.

How many employees does Protagonist Therapeutics have?

Protagonist Therapeutics employs 79 workers across the globe.

What is Protagonist Therapeutics' official website?

The official website for Protagonist Therapeutics is www.protagonist-inc.com.

Where are Protagonist Therapeutics' headquarters?

Protagonist Therapeutics is headquartered at 7707 GATEWAY BOULEVARD SUITE 140, NEWARK CA, 94560.

How can I contact Protagonist Therapeutics?

Protagonist Therapeutics' mailing address is 7707 GATEWAY BOULEVARD SUITE 140, NEWARK CA, 94560. The company can be reached via phone at (510) 474-0170 or via email at [email protected].


This page was last updated on 1/23/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.